CN111838674A - Composition with anti-sugar effect and application thereof - Google Patents

Composition with anti-sugar effect and application thereof Download PDF

Info

Publication number
CN111838674A
CN111838674A CN202010749801.3A CN202010749801A CN111838674A CN 111838674 A CN111838674 A CN 111838674A CN 202010749801 A CN202010749801 A CN 202010749801A CN 111838674 A CN111838674 A CN 111838674A
Authority
CN
China
Prior art keywords
extract
parts
composition
anthocyanin
content
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202010749801.3A
Other languages
Chinese (zh)
Inventor
李春美
杜霞
李凯凯
朱琳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Huazhong Agricultural University
Original Assignee
Huazhong Agricultural University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Huazhong Agricultural University filed Critical Huazhong Agricultural University
Priority to CN202010749801.3A priority Critical patent/CN111838674A/en
Publication of CN111838674A publication Critical patent/CN111838674A/en
Pending legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105Plant extracts, their artificial duplicates or their derivatives
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/03Organic compounds
    • A23L29/035Organic compounds containing oxygen as heteroatom
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/30Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/60Moraceae (Mulberry family), e.g. breadfruit or fig
    • A61K36/605Morus (mulberry)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/73Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/81Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
    • A61K36/815Lycium (desert-thorn)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs

Abstract

The invention discloses a composition with an anti-sugar effect and application thereof, wherein the composition comprises the following raw materials in parts by weight: 5-10 parts of mulberry extract, 5-10 parts of raspberry extract, 15-20 parts of strawberry extract, 5-10 parts of roselle extract, 15-20 parts of lycium ruthenicum extract, 5-10 parts of persimmon tannin cracking product, 35-50 parts of oligomeric inulin and 1-5 parts of citric acid; the composition is used for preparing medicines or health-care foods for treating, delaying or relieving ACEs related diseases; the composition can obviously inhibit the formation of AGEs, simultaneously shows extremely strong free radical scavenging capacity, can be gradually popularized to the fields of cosmetics, foods and medicines, and has wide future prospect.

Description

Composition with anti-sugar effect and application thereof
Technical Field
The invention relates to the technical field of health-care food, in particular to a composition with an anti-sugar effect and application thereof.
Background
Advanced glycation end products (AGEs) can be divided into endogenous AGEs and exogenous AGEs. Endogenous AGEs are produced by reaction of proteins in organisms and redundant saccharides, and particularly have the highest content in blood and cells of patients with renal failure and diabetes, so that physiological changes such as diabetes, renal failure and the like are influenced, and human health is seriously influenced. Exogenous AGEs refer to AGEs taken in by organisms from the outside, mostly carried in by food, also called food-borne AGEs.
As the AGEs can change the structure and the function of protein, the accumulation of the AGEs has great relation with diseases such as neuropathy, Alzheimer syndrome, atherosclerosis and the like and can cause diabetic complications such as diabetic nephropathy, retinopathy and the like, and in addition, the AGEs can be combined with a specific receptor of a cell membrane and cause the pathological changes of tissues and organs by abnormally activating a signal path such as NF-kappa B, MAPK and the like. At present, AGEs inhibitors such as aspirin and aminoguanidine used in medical clinic all have certain toxic and side effects. Therefore, there is a need to develop novel AGEs inhibitors that are free of adverse effects.
Disclosure of Invention
In view of the problems of the prior art, the invention aims to provide a composition with anti-saccharification effect and application thereof.
In order to achieve the purpose, the invention provides the following scheme:
the invention provides a composition with an anti-sugar effect, which comprises the following raw materials in parts by weight: 5-10 parts of mulberry extract, 5-10 parts of raspberry extract, 15-20 parts of strawberry extract, 5-10 parts of roselle extract, 15-20 parts of lycium ruthenicum extract, 5-10 parts of persimmon tannin cracking product, 35-50 parts of oligomeric inulin and 1-5 parts of citric acid. The main component of the fruit extract is anthocyanin which is extremely unstable in aqueous solution, so in order to improve the stability of the anthocyanin and increase the activity of the anthocyanin for inhibiting AGEs, the invention adds oligomer procyanidin as a stabilizer and a synergist of the anthocyanin.
As a further improvement of the invention, the content of Cy-3-glc and Cy-3-rut2 main anthocyanins in the mulberry extract is not less than 47.5% and 20.5%; the content of Cy-3-soph and Cy-3-glc 2 major anthocyanins in the red raspberry extract is not less than 30% and 37.5%; the Pg-3-glc content in the strawberry extract is not less than 60%; the content of 3 kinds of anthocyanin Dp-3-sam, Dp-3-glc and Cy-3-glc in the Hibiscus sabdariffa extract is not less than 8.5%, 14.5% and 10%; the content of petunidin-3-rutinoside in the Lycium ruthenicum Murr extract is not less than 60%.
As a further improvement of the invention, the persimmon tannin cracking product is persimmon procyanidin oligomer obtained by carrying out high-pressure catalytic hydrogenolysis on persimmon tannin, the average polymerization degree is not more than 3, and the content of A-ECG and EGCG dimer is not less than 10%.
As a further improvement of the invention, the polymerization degree of the oligoinulin is not more than 10.
As a further improvement of the invention, the preparation methods of the mulberry extract, the raspberry extract, the strawberry extract, the roselle extract and the lycium ruthenicum extract are as follows: respectively weighing and grinding the mulberries, the red raspberries, the strawberries, the roselle and the lycium ruthenicum mill, extracting by adopting hydrochloric acid methanol, enriching by AB-8 macroporous resin, eluting, and preparing by medium pressure chromatography to obtain a crude extract rich in anthocyanin.
The mulberry extract, the raspberry extract, the strawberry extract, the roselle extract and the lycium ruthenicum extract are mainly anthocyanin crude extracts, and the specific preparation method comprises the following steps: weighing Mori fructus, Rubi fructus, strawberry, calyx Hibisci Sabdariffae and fructus Lycii respectively, grinding, adding 0.1% hydrochloric acid-containing methanol at a ratio of material to liquid (m/m) of 1:2, placing in dark place, performing ultrasound treatment at 40 deg.C for 30min, filtering the extractive solution with gauze, performing ultrasound treatment on the filter residue under the same conditions for 3 times, mixing the extractive solutions, and removing methanol with rotary evaporator under vacuum condition at 45 deg.C. Filtering the anthocyanin concentrated solution with Buchner funnel, adjusting pH to 1.5, loading into chromatographic column filled with AB-8 resin material, adsorbing for 60min, removing impurities such as protein and sugar with 0.1% volume fraction hydrochloric acid distilled water, detecting eluate with phenol-sulfuric acid method to colorless, eluting anthocyanin with 60% ethanol with pH of 2.5, collecting eluate, and removing ethanol by rotary evaporation at 45 deg.C under vacuum condition. Extracting the concentrated solution with ethyl acetate at a ratio of 1:1(v/v), repeatedly extracting for 3 times under the same conditions, combining water phases, vacuum concentrating, freeze-drying, and further purifying by medium-pressure preparative chromatography to obtain crude anthocyanin extract.
The invention also provides application of the composition with the anti-sugar effect in preparing medicines or health-care foods for treating, delaying or relieving ACEs related diseases.
As a further improvement of the invention, the AGEs-related diseases are diabetes, atherosclerosis, chronic kidney disease, liver disease or neurodegenerative disease.
As a further improvement of the invention, the medicine also comprises pharmaceutically acceptable auxiliary materials, and the health food also comprises the auxiliary materials which are acceptable in food science.
As a further improvement of the invention, the medicament is in the form of oral preparation or injection preparation.
As a further improvement of the invention, the oral preparation is tablets, powder, capsules, granules, pills, powder, paste or oral liquid.
The invention discloses the following technical effects:
the invention provides a composition with the anti-sugar effect, which takes a plurality of fruit extracts rich in anthocyanin as raw materials, fully utilizes the synergistic effect of the anthocyanin and the oligomer, and adds oligoinulin which can improve the taste and has stable anthocyanin and procyanidin and citric acid which can improve the taste on the basis of the synergistic effect of the anthocyanin and the oligomer. The composition with the anti-sugar effect can obviously inhibit the formation of AGEs and simultaneously shows extremely strong free radical scavenging capacity. In summary, all experiments demonstrated that the composition had a significant effect of inhibiting the formation of AGEs. The raw materials related by the invention are all food raw materials, have small side effect and high safety, can be applied to human bodies, can be gradually popularized to the fields of cosmetics, foods and medicines, and have wide future prospects.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings needed to be used in the embodiments will be briefly described below, and it is obvious that the drawings in the following description are only some embodiments of the present invention, and it is obvious for those skilled in the art to obtain other drawings without inventive exercise.
FIG. 1 is a high performance liquid chromatogram of anthocyanin content in a mulberry extract, wherein A is a high performance liquid chromatogram of the mulberry extract at a wavelength of 280nm, and B is a high performance liquid chromatogram of the mulberry extract at a wavelength of 520 nm;
FIG. 2 is a high performance liquid chromatogram of anthocyanin content in a raspberry extract, wherein A is a high performance liquid chromatogram of a raspberry extract at a wavelength of 280nm, and B is a high performance liquid chromatogram of a raspberry extract at a wavelength of 520 nm;
FIG. 3 is a high performance liquid chromatogram of the anthocyanin content of a strawberry extract, wherein A is the high performance liquid chromatogram of the strawberry extract at a wavelength of 280nm, and B is the high performance liquid chromatogram of the strawberry extract at a wavelength of 520 nm;
FIG. 4 is a high performance liquid chromatogram of the anthocyanin content of Hibiscus sabdariffa extract, wherein A is the high performance liquid chromatogram of the Hibiscus sabdariffa extract at a wavelength of 280nm, and B is the high performance liquid chromatogram of the Hibiscus sabdariffa extract at a wavelength of 520 nm;
FIG. 5 is a high performance liquid chromatogram of the anthocyanin content of Lycium ruthenicum Murr extract, wherein A is a high performance liquid chromatogram of Lycium ruthenicum Murr extract at a wavelength of 280nm, and B is a high performance liquid chromatogram of Lycium ruthenicum Murr extract at a wavelength of 520 nm;
FIG. 6 is a graph of the amelioration of high AGEs feed toxicity by a preferred composition of the present invention, wherein A is a graph of the significant inhibition of the activation of the RAGE-p38MAPK-NF- κ B signaling pathway by the preferred composition of the present invention, and B is a graph of the significant inhibition of the expression of TNF- α and IL-6 inflammatory factors in the liver by the preferred composition of the present invention.
Detailed Description
Reference will now be made in detail to various exemplary embodiments of the invention, the detailed description should not be construed as limiting the invention but as a more detailed description of certain aspects, features and embodiments of the invention.
It is to be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. Further, for numerical ranges in this disclosure, it is understood that each intervening value, between the upper and lower limit of that range, is also specifically disclosed. Every smaller range between any stated value or intervening value in a stated range and any other stated or intervening value in a stated range is encompassed within the invention. The upper and lower limits of these smaller ranges may independently be included or excluded in the range.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although only preferred methods and materials are described herein, any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention. All documents mentioned in this specification are incorporated by reference herein for the purpose of disclosing and describing the methods and/or materials associated with the documents. In case of conflict with any incorporated document, the present specification will control.
It will be apparent to those skilled in the art that various modifications and variations can be made in the specific embodiments of the present disclosure without departing from the scope or spirit of the disclosure. Other embodiments will be apparent to those skilled in the art from consideration of the specification. The specification and examples are exemplary only.
As used herein, the terms "comprising," "including," "having," "containing," and the like are open-ended terms that mean including, but not limited to.
EXAMPLE 1 preparation of crude anthocyanin extract
Respectively taking 50g of mulberry, raspberry, strawberry, roselle and lycium ruthenicum, grinding, adding 100ml of methanol containing 0.1% hydrochloric acid at a material-liquid ratio (m/m) of 1:2, placing in a dark place, carrying out ultrasonic treatment at 40 ℃ for 30min, filtering the extracting solution with gauze, repeatedly carrying out ultrasonic treatment on filter residues for 3 times under the same condition, combining the extracting solutions, and removing the methanol by using a rotary evaporator under the vacuum condition of 45 ℃. Filtering the anthocyanin concentrated solution with Buchner funnel, adjusting pH to 1.5, loading into chromatographic column filled with AB-8 resin material, adsorbing for 60min, removing impurities such as protein and sugar with 0.1% volume fraction hydrochloric acid distilled water, detecting eluate with phenol-sulfuric acid method to colorless, eluting anthocyanin with 60% ethanol with pH of 2.5, collecting eluate, and removing ethanol by rotary evaporation at 45 deg.C under vacuum condition. Extracting the concentrated solution with ethyl acetate at a ratio of 1:1(v/v), repeating the extraction for 3 times under the same conditions, combining the water phases, vacuum concentrating, and freeze drying to obtain 5 kinds of crude anthocyanin extracts.
HPLC detection analysis of 5 kinds of anthocyanin crude extracts
1mg of Cy-3-glc standard substance is quantitatively weighed and dissolved in HCl methanol solution with volume fraction of 0.1% to prepare 1mg/ml Cy-3-glc standard solution, and then the standard solution is filtered by a 0.45 mu m filter membrane into a brown liquid phase bottle for liquid phase analysis. The liquid chromatography conditions were as follows: a Waters C18 column (250 mm. times.4.6 mm,5 μm) was used; mobile phase A: 5% formic acid water, mobile phase B: methanol; gradient elution conditions: 0-10 min, 5% -20% of B; 10min to 15min, 20 percent to 20 percent of B; 15 min-30 min, 20% -25% B; 30-35 min, 25-25% B; 35-40 min, 25-33% B; 40 min-42 min, 33% -5% B; 42min to 47min, 5 percent to 5 percent of B; the flow rate is 1mL/min, the detection wavelength is 520nm by a PDA detector, the sample introduction amount of the standard substance is 1, 2, 4, 8 and 16 mu L, the sample introduction is repeated for 3 times in each volume, and the average peak area of each sample introduction volume is calculated. The mass (. mu.g) was plotted on the abscissa and the peak area on the ordinate, giving a standard curve of y 2000000x-42033 (R)2=0.9999)。
Detection of anthocyanin content in 5 kinds of anthocyanin crude extracts
Respectively taking 5 anthocyanin crude extracts, quantitatively dissolving with HCl methanol containing 0.1% of volume fraction, taking a proper amount of dissolving solution, filtering with a filter membrane of 0.45 mu m, transferring into a brown liquid phase bottle, and analyzing the liquid phase conditions in the same HPLC detection of the 5 anthocyanin crude extracts, wherein the detection wavelengths are 280nm and 520 nm. And substituting the obtained peak area into the standard curve for quantitative calculation.
Separating 5 kinds of anthocyanin crude extract with MPPSS
300mg of 5 kinds of crude extracts of anthocyanin are respectively taken and ultrasonically dissolved by 2mL of analytically pure methanol and filtered by a filter membrane with the diameter of 0.45 mu m for standby. The gradient elution conditions of the crude extracts of the anthocyanin of the mulberries and the red raspberries are as follows: 0-2 min, 20% B; 2-22 min, 20% -30% of B; 22-32 min, 30-40% of B, and the gradient elution conditions of the crude extracts of strawberry and roselle anthocyanin are as follows: 0-2 min, 20% B; 2-22 min, 20-30% of B, 22-32 min, 30-40% of B, 32-47 min and 40-45% of B, wherein the elution conditions of the lycium ruthenicum anthocyanin crude extract are as follows: 0-2 min, 20% B; 2-22 min, 20% -30% of B; 22-32 min, 30% -40% B; 32-47 min, 40-45% B; 47-57 min, 45-60% of B, a detection wavelength of 280nm, a preparation column model Flash C18(80g, 20-35 μm, 100A), 2 columns connected in series, and a sample is subjected to peak cutting and collection, wherein the collection unit is 10 mL.
In the MPSS separation process, research shows that anthocyanin is stable under an acidic condition, tailing conditions can be effectively reduced and the separation effect can be well improved by adding formic acid, the flow rate is 40mL/min, the A mobile phase is 2% formic acid water, and the B mobile phase is methanol.
Determining content of main anthocyanin in the crude extract
Respectively mixing freeze-dried samples of different anthocyanin components obtained by MPSSs separation according to the same proportion, dissolving a certain amount of the freeze-dried samples by using 0.1% HCl methanol, filtering the mixture by using a 0.45 mu m filter membrane, performing liquid phase analysis, performing HPLC detection analysis on 5 kinds of anthocyanin crude extracts under the same liquid phase condition, injecting 10 mu L of the sample, and detecting the wavelengths of 280nm and 520 nm.
Structural identification of the obtained anthocyanin fraction by UPLC-MS
Chromatographic column
Figure BDA0002609677900000081
BEH Waters C18(2.1 mm. times.100 mm,1.7 μm); the sample volume is 2 mu L; the column temperature is 45 ℃; the flow rate is 0.4 mL/min; mobile phase A: 0.1% formic acid water, mobile phase B: methanol; elution conditions: 0-0.5 min, 2% -2% B; 0.5-1 min, 2% -5% of B; 1-2 min, 5% -10% of B; 2-5 min, 10% -20% of B; 5-8 min, 20% -100% B; 8-11 min, 100% B; 11-11.5 min, 100% -5% B; 11.5-13 min, 5% -5% B. Electrospray ionization ion source, scanning particle range: 50-1000 m/z, positive ion mode, atomizer pressure of 40psi, gas flow rate of 10L/min, dryer temperature of 350 ℃, capillary voltage of 3500V.
The detection result of the high performance liquid chromatography of anthocyanin content in the mulberry extract is shown in figure 1, wherein A is the high performance liquid chromatogram of the mulberry extract at the wavelength of 280nm, and B is the high performance liquid chromatogram of the mulberry extract at the wavelength of 520 nm. As can be seen from fig. 1A and 1B, there are 2 main peaks and fewer peaks at both wavelengths, and the content of 2 main anthocyanins in mulberry was calculated to be 47.5% and 20.5% by using cyanidin-3-glucoside (Cy-3-glc) as a standard.
The high performance liquid chromatography detection result of anthocyanin content in the red raspberry extract is shown in fig. 2, wherein A is the high performance liquid chromatogram of the red raspberry extract at the wavelength of 280nm, and B is the high performance liquid chromatogram of the red raspberry extract at the wavelength of 520 nm. As can be seen from FIG. 2, the crude extract of raspberry anthocyanin has 2 main peaks at 520nm, and many impurity peaks before the 2 major peaks of anthocyanin at 280 nm. Taking Cy-3-glc as a standard substance, calculating the contents of 2 main anthocyanins in the crude extract of raspberry anthocyanin to be 30% and 37.5% respectively.
The detection result of the strawberry extract anthocyanin content by high performance liquid chromatography is shown in figure 3, wherein A is a high performance liquid chromatogram of the strawberry extract at a wavelength of 280nm, and B is a high performance liquid chromatogram of the strawberry extract at a wavelength of 520 nm. As can be seen from FIG. 3, there are 1 major peak at 520nm wavelength, indicating that the strawberry flower extract mainly contains 1 anthocyanin, while at 280nm wavelength, there are more impurities before and after the major anthocyanin peak, and the content of 1 major anthocyanin in the strawberry anthocyanin crude extract is 60% using Cy-3-glc as the standard.
The high performance liquid chromatography detection result of anthocyanin content in Hibiscus sabdariffa extract is shown in figure 4, wherein A is high performance liquid chromatogram of Hibiscus sabdariffa extract at wavelength of 280nm, and B is high performance liquid chromatogram of Hibiscus sabdariffa extract at wavelength of 520 nm. As can be seen from FIG. 4, the crude Hibiscus sabdariffa anthocyanin contains 3 major anthocyanins at 520nm, and contains some impurities before the major peaks of 3 anthocyanins at 280nm, and the content of 3 anthocyanins in Hibiscus sabdariffa is calculated to be 8.5%, 14.5% and 10% respectively, using Cy-3-glc as standard.
The high performance liquid chromatography detection result of anthocyanin content in Lycium ruthenicum Murr extract is shown in FIG. 5, wherein A is a high performance liquid chromatogram of Lycium ruthenicum Murr extract at a wavelength of 280nm, and B is a high performance liquid chromatogram of Lycium ruthenicum Murr extract at a wavelength of 520 nm. As can be seen from FIG. 5, there are only 1 main peak at 520nm wavelength, and 280nm liquid phase diagram shows that many non-anthocyanin substances are present before the main peak of anthocyanin, and the content of 1 main anthocyanin contained in Lycium ruthenicum is calculated to be 60% by taking Cy-3-glc as a standard.
Example 2
The composition with the anti-sugar effect comprises the following raw materials in parts by weight: 5 parts of mulberry extract, 8 parts of raspberry extract, 15 parts of strawberry extract, 6 parts of roselle extract, 15 parts of lycium ruthenicum extract, 10 parts of persimmon tannin cracking product, 35 parts of oligomeric inulin and 1 part of citric acid. Mixing according to weight ratio.
Example 3
The composition with the anti-sugar effect comprises the following raw materials in parts by weight: 10 parts of mulberry extract, 5 parts of raspberry extract, 18 parts of strawberry extract, 8 parts of roselle extract, 18 parts of lycium ruthenicum extract, 6 parts of persimmon tannin cracking product, 40 parts of oligoinulin and 3 parts of citric acid. Mixing according to weight ratio.
Example 4
The composition with the anti-sugar effect comprises the following raw materials in parts by weight: 8 parts of mulberry extract, 6 parts of raspberry extract, 19 parts of strawberry extract, 5 parts of roselle extract, 16 parts of lycium ruthenicum extract, 7 parts of persimmon tannin cracking product, 45 parts of oligoinulin and 4 parts of citric acid. Mixing according to weight ratio.
Example 5
The composition with the anti-sugar effect comprises the following raw materials in parts by weight: 9 parts of mulberry extract, 9 parts of raspberry extract, 20 parts of strawberry extract, 10 parts of roselle extract, 15 parts of lycium ruthenicum extract, 5 parts of persimmon tannin cracking product, 50 parts of oligoinulin and 5 parts of citric acid. Mixing according to weight ratio.
Example 6
The composition with the anti-sugar effect comprises the following raw materials in parts by weight: 10 parts of mulberry extract, 10 parts of raspberry extract, 18 parts of strawberry extract, 8 parts of roselle extract, 20 parts of lycium ruthenicum extract, 7 parts of persimmon tannin cracking product, 48 parts of oligoinulin and 3 parts of citric acid. Mixing according to weight ratio.
Evaluation of anti-glycation Effect
The inhibition of AGEs formation by the compositions of examples 2-6 was evaluated using a glucose- β -Lg mimetic system. According to the fluorescence of AGEs, an F-4600 fluorescence spectrometer is adopted to determine the fluorescence intensity of fluorescent AGEs after a blank control group and a composition test group are added for reaction for 7d under the conditions of an excitation wavelength of 325nm and an emission wavelength of 440nm, and the inhibition rate of the composition to the fluorescent AGEs is calculated, wherein the calculation method comprises the following steps:
Figure BDA0002609677900000121
wherein, F0-fluorescence intensity of blank control group; f1-fluorescence intensity of test group
The results show that the optimal composition (the composition indicated in example 2) of the present invention has a significant function of inhibiting the production of glycosylation products, and the IC thereof50At 378. mu.g/ml, IC of examples 3, 4, 5, 650475. mu.g/ml, 492. mu.g/ml, 486. mu.g/ml and 428. mu.g/ml, respectively.
Mouse experiments to evaluate the anti-glycation of the compositions of the invention
SPF rats are divided into three groups and fed with normal feed, high-dose AGEs feed and feed (0.5 percent, w/w) containing a composition (the composition in example 2: 5 parts of mulberry extract, 8 parts of raspberry extract, 15 parts of strawberry extract, 6 parts of roselle extract, 15 parts of Lycium ruthenicum extract, 10 parts of persimmon tannin cleavage product, 35 parts of oligoinulin and 1 part of citric acid) respectively, and the expression of RAGE, p38MAPK and NF-kappa B in the liver of the rats is detected by immunohistochemical staining, and the result is shown in figure 6, and shows that the composition can obviously inhibit the activation of a RAGE-p38 MAPK-NF-kappa B signal channel. The expression of the inflammatory factors TNF-alpha (24%) and IL-6 (50%) in the liver is detected by an ELISA method, and the result shows that the composition provided by the invention can obviously reduce the expression of the inflammatory factors. These results indicate that the compositions of the present invention have a significant in vivo anti-glycation effect.
The above-described embodiments are merely illustrative of the preferred embodiments of the present invention, and do not limit the scope of the present invention, and various modifications and improvements of the technical solutions of the present invention can be made by those skilled in the art without departing from the spirit of the present invention, and the technical solutions of the present invention are within the scope of the present invention defined by the claims.

Claims (10)

1. The composition with the anti-sugar effect is characterized by comprising the following components in parts by weight: 5-10 parts of mulberry extract, 5-10 parts of raspberry extract, 15-20 parts of strawberry extract, 5-10 parts of roselle extract, 15-20 parts of lycium ruthenicum extract, 5-10 parts of persimmon tannin cracking product, 35-50 parts of oligomeric inulin and 1-5 parts of citric acid.
2. The composition with the anti-sugar effect according to claim 1, wherein the content of Cy-3-glc and Cy-3-rut2 major anthocyanins in the mulberry extract is not less than 47.5% and 20.5%; the content of Cy-3-soph and Cy-3-glc 2 major anthocyanins in the red raspberry extract is not less than 30% and 37.5%; the Pg-3-glc content in the strawberry extract is not less than 60%; the content of 3 kinds of anthocyanin Dp-3-sam, Dp-3-glc and Cy-3-glc in the Hibiscus sabdariffa extract is not less than 8.5%, 14.5% and 10%; the content of petunidin-3-rutinoside in the Lycium ruthenicum Murr extract is not less than 60%.
3. The composition with anti-sugar effect as claimed in claim 1, wherein the persimmon tannin cracking product is persimmon procyanidin oligomer obtained by subjecting persimmon tannin to high pressure catalytic hydrogenolysis, the average degree of polymerization is not more than 3, and the content of A-ECG and EGCG dimer is not less than 10%.
4. The composition having an anti-sugar effect according to claim 1, wherein the polymerization degree of oligoinulin is not more than 10.
5. The composition with the sugar-resistant effect according to claim 1, wherein the mulberry extract, the raspberry extract, the strawberry extract, the roselle extract and the lycium ruthenicum extract are prepared by the following steps: weighing and grinding mulberries, red raspberries, strawberries, roselle and lycium ruthenicum mill respectively, extracting by adopting hydrochloric acid methanol, enriching by AB-8 macroporous resin, enriching by medium-pressure countercurrent chromatography, and eluting to obtain a crude extract rich in anthocyanin.
6. Use of the composition with anti-sugar effect according to any one of claims 1 to 5 in the preparation of a medicament or health food for treating, delaying or alleviating ACEs-related diseases.
7. The use according to claim 6, wherein the AGEs-related diseases are diabetes, atherosclerosis, chronic kidney disease, liver disease or neurodegenerative disease.
8. The use according to claim 6, wherein the medicament further comprises pharmaceutically acceptable excipients and the health food further comprises dietetically acceptable excipients.
9. The use according to claim 8, wherein the medicament is in the form of an oral formulation or an injectable formulation.
10. The use according to claim 9, wherein the oral formulation is a tablet, powder, capsule, granule, pill, powder, paste, or oral liquid.
CN202010749801.3A 2020-07-30 2020-07-30 Composition with anti-sugar effect and application thereof Pending CN111838674A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010749801.3A CN111838674A (en) 2020-07-30 2020-07-30 Composition with anti-sugar effect and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010749801.3A CN111838674A (en) 2020-07-30 2020-07-30 Composition with anti-sugar effect and application thereof

Publications (1)

Publication Number Publication Date
CN111838674A true CN111838674A (en) 2020-10-30

Family

ID=72945972

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010749801.3A Pending CN111838674A (en) 2020-07-30 2020-07-30 Composition with anti-sugar effect and application thereof

Country Status (1)

Country Link
CN (1) CN111838674A (en)

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070060533A1 (en) * 2003-10-24 2007-03-15 Meiji Seika Kaisha Ltd. Novel inhibitor of the formation of advanced glycation end product and aldose reductase inhibitor
CN102718817A (en) * 2011-03-31 2012-10-10 成都华高药业有限公司 Method for preparing anthocyanin extract from black bean peel
CN105410546A (en) * 2015-11-27 2016-03-23 魏海青 Anthocyanin-rich composite plant beverage and preparation method thereof
JP2017141201A (en) * 2016-02-12 2017-08-17 株式会社東洋新薬 Glycosylation inhibitor
CN108409703A (en) * 2018-06-07 2018-08-17 中国农业大学 A kind of method of anthocyanin of the Simulation moving bed separation with delaying senility function
CN109090611A (en) * 2018-10-26 2018-12-28 汤臣倍健股份有限公司 A kind of AGEs composite inhibiting and its application, preparation method, preparation
CN109938350A (en) * 2019-04-10 2019-06-28 浙江省农业科学院 A kind of myrica ruba marc alcohol extract and preparation method with effect of lowering blood sugar
CN110574927A (en) * 2019-08-30 2019-12-17 北京姿美堂生物技术有限公司 Anti-saccharification composition and preparation method thereof
CN110664868A (en) * 2019-10-15 2020-01-10 无限极(中国)有限公司 Composition with anti-glycosylation effect and application thereof
CN111205259A (en) * 2020-01-08 2020-05-29 华中农业大学 Preparation method and application of persimmon oligomeric proanthocyanidins

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070060533A1 (en) * 2003-10-24 2007-03-15 Meiji Seika Kaisha Ltd. Novel inhibitor of the formation of advanced glycation end product and aldose reductase inhibitor
CN102718817A (en) * 2011-03-31 2012-10-10 成都华高药业有限公司 Method for preparing anthocyanin extract from black bean peel
CN105410546A (en) * 2015-11-27 2016-03-23 魏海青 Anthocyanin-rich composite plant beverage and preparation method thereof
JP2017141201A (en) * 2016-02-12 2017-08-17 株式会社東洋新薬 Glycosylation inhibitor
CN108409703A (en) * 2018-06-07 2018-08-17 中国农业大学 A kind of method of anthocyanin of the Simulation moving bed separation with delaying senility function
CN109090611A (en) * 2018-10-26 2018-12-28 汤臣倍健股份有限公司 A kind of AGEs composite inhibiting and its application, preparation method, preparation
CN109938350A (en) * 2019-04-10 2019-06-28 浙江省农业科学院 A kind of myrica ruba marc alcohol extract and preparation method with effect of lowering blood sugar
CN110574927A (en) * 2019-08-30 2019-12-17 北京姿美堂生物技术有限公司 Anti-saccharification composition and preparation method thereof
CN110664868A (en) * 2019-10-15 2020-01-10 无限极(中国)有限公司 Composition with anti-glycosylation effect and application thereof
CN111205259A (en) * 2020-01-08 2020-05-29 华中农业大学 Preparation method and application of persimmon oligomeric proanthocyanidins

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
刘莉: "《蔬菜营养学》", 30 June 2014, 天津大学出版社 *
张朝红 等: "桑椹花色苷对晚期糖基化末端产物抑制作用及其机制分析", 《现代食品科技》 *
杜霞 等: "中压快速分离系统大量制备高纯度桑葚和树莓花色苷的工艺研究", 《食品工业科技》 *
贾东升 等: "黑枸杞花色苷对酒精性肝损伤的保护作用", 《食品研究与开发》 *

Similar Documents

Publication Publication Date Title
US9770479B2 (en) Extract of Rehmannia glutinasa Libosch for reducing blood sugar, reducing blood fat, treating leukemia, and preparation method and uses thereof
CN102600219B (en) Total flavone extract of abelmoschus manihot and preparing method of total flavone extract
CA2559826C (en) Traditional chinese medicine preparation for cardio-cerebral blood vessel diseases and its preparing method
Zhou et al. Separation and purification of α-glucosidase inhibitors from Polygonatum odoratum by stepwise high-speed counter-current chromatography combined with Sephadex LH-20 chromatography target-guided by ultrafiltration–HPLC screening
CN101985644B (en) Momordica charantia polypeptide, preparation method and application thereof
KR20060069349A (en) Method for preparing a centella asiatica extract rich in madecassoside and in terminoloside
CN103110651A (en) Application of active ingredient namely loganin in dogwood in preparation of medicaments for treating diabetes
CN111018933A (en) Fructus momordicae extract product and preparation method and application thereof
CN103006878B (en) A kind of fresh rehmannia root total glycosides extractive and preparation method and application
CN105859803B (en) A kind of preparation method of galloyl glucose
CN102134268B (en) Method for preparing panax japonicus saponin IVa and application of panax japonicus saponin IVa in preparing a medicament for protecting liver and lowering transaminase
CN107349244B (en) Extraction method of malonyl ginsenoside
CN113499353A (en) Preparation method and application of ginseng and pilose antler refined component with anti-Alzheimer disease activity
CN113577239A (en) American ginseng glycopeptide and preparation method and application thereof
CN110680802B (en) Tetrandrine injection and preparation method thereof
CN112159451A (en) Gynostemma pentaphylla saponin extract and preparation method thereof
CN115433248B (en) Novel amino acid derivative separation and identification in red ginseng and novel application thereof
CN111838674A (en) Composition with anti-sugar effect and application thereof
CN101422529B (en) Preparation method of traditional Chinese medicine preparation
CN103381200A (en) White mulberry root-bark total alkaloid extract and preparation and application thereof
CN113185618B (en) Anti-alcoholic liver injury rhizoma atractylodis macrocephalae polysaccharide and preparation method and application thereof
CA2455655C (en) A glycoprotein with antidiabetic, antihypertensive, antiobesity and antihyperlipidemic effects from grifola frondosa, and a method for preparing same
KR100839185B1 (en) Composition comprising plantamajoside for treating or preventing diabete and diabetic complication
CN113670680A (en) Preparation method of acarbose impurity reference substance
CN107513092B (en) Malonyl ginsenoside Rb1Preparation method and medical application thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20201030